|
Title
|
Publication Date
|
Price
|
Relevance
|
Migraine Therapeutics
Pipeline Assessment and Market Forecasts to 2016
|
Jul 2010 |
£1,265 |
100% |
|
Migraine Therapy Area Pipeline Report
|
Mar 2011 |
£945 |
99% |
The Global Pain Therapeutics Market
4th Edition: Market Trends & R&D Insights
|
Nov 2010 |
£1,105 |
90% |
|
AGA Medical Corporation Product Pipeline Analysis
|
Jan 2009 |
£475 |
89% |
Central Nervous System Disorders Therapeutics Market to 2017
Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half The Market Value in 2010
|
Nov 2011 |
£2,215 |
88% |
Pain Management Therapeutics Market to 2017
Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
|
Nov 2011 |
£2,215 |
88% |
Anticonvulsants Market to 2016
Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies
|
Jan 2011 |
£2,215 |
87% |
|
NMT Medical, Inc. Product Pipeline Analysis
|
Jan 2009 |
£475 |
82% |
|
The Global Market for Pain Management Drugs and Devices
|
Aug 2009 |
£3,065 |
80% |
Global Cardiovascular Devices Pipeline Landscape
Analysis of Key Upcoming Products and Technologies
|
Jan 2010 |
£1,265 |
70% |
Oral Drug Delivery Market
Controlled and Sustained Release to be Major Revenue Generators
|
Nov 2010 |
£2,215 |
70% |
|
St. Jude Medical Inc. Product Pipeline Analysis
|
Jan 2009 |
£475 |
67% |
Pipeline Insight: Breakthrough Pain
Fast-acting players will capture majority market share
|
Nov 2006 |
£7,210 |
64% |
Zolmitriptan - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
62% |
Eletriptan - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
62% |
Naratriptan - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
62% |
Rizatriptan - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
62% |
Almotriptan - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
62% |
Sumatriptan - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
62% |
Frovatriptan - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
62% |
Topiramate - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
62% |
Diclofenac - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
62% |
Zolmitriptan - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
60% |
Eletriptan - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
60% |
Naratriptan - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
60% |
Rizatriptan - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
60% |
Almotriptan - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
60% |
Sumatriptan - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
60% |
Frovatriptan - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
60% |
Topiramate - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
60% |
